Nov 20, 2024, 12:34 | Dialogues

Dr. Richard Pazdur's 25 Year WAR on Cancer at the FDA!

In a career that spans nearly half a century in oncology, including 25 years at…

Nov 20, 2024, 11:30 | Insight

Flora Xydaki: Biomarkers in Oncology - Transforming Cancer Diagnosis and Treatment

Flora Xydaki, Project Associate at BTHT, shared a post on LinkedIn: "Biomarkers in Oncology: Transforming Cancer…

Nov 16, 2024, 11:59 | Dialogues

OncoDaily: France Bureau // vol. 4

In this week’s update, we cover key developments from the 56th SIOP Congress, including the…

Nov 14, 2024, 15:58 | Insight

Iván R. González: Warning on Sotorasib Treatment for Advanced Lung Cancer

Iván R. González, Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla, shared on X:…

Nov 13, 2024, 10:47 | Blog

FDA approves obecabtagene autoleucel for relapsed or refractory B-cell precursor ALL

On November 8, 2024, the Food and Drug Administration approved obecabtagene autoleucel (Aucatzyl, Autolus Inc.),…

Nov 12, 2024, 19:26 | Blog

Jim Palma: Think Tank on Advancing Precision Medicine in Rare Cancers

Jim Palma, Chief Executive Officer at TargetCancer Foundation, shared a post on LinkedIn: "Very hard…

Nov 11, 2024, 15:46 | Blog

Tanja Obradovic: New treatment option for patients with low PDL-1 expression in head and neck cancers

Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post on…

Nov 10, 2024, 01:23 | Blog

Daniel O'Day: Gilead Sciences announces third quarter financial results

Daniel O'Day, Chairman and Chief Executive Officer of Gilead Sciences and Board Member of PhRMA and…

Nov 9, 2024, 14:35 | Drugs

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

The FDA has broadened its approval of methotrexate (Jylamvo) to include the treatment of pediatric…

Nov 7, 2024, 15:45 | Insight

Four new drugs approved by the FDA in October summarized by Samuel Hume

Samuel Hume, Scientist at the University of Oxford, shared a post on X: “The FDA…

Nov 5, 2024, 14:59 | Blog

FDA Approval for Advanced Gastric Cancer Treatment: A New Option for Patients - The Babak Lab

The Babak Lab posted on LinkedIn: "FDA Approval for Advanced Gastric Cancer Treatment: A New…

Nov 5, 2024, 05:47 | Opinion

Kamala Harris vs Donald Trump on Cancer: From Cancer Moonshot to Right to Act, Funding, Research and Future

Cancer remains one of the most pressing health challenges of our time, affecting millions of…

Nov 4, 2024, 09:03 | Insight

Dr. Richard Pazdur: 25 Years of Transforming Oncology Drug Development at the FDA

In a career that spans nearly half a century in oncology, including 25 years at…

Nov 2, 2024, 17:37 | Blog

How to Foster the Next Innovation in Oncology Clinical Development and Medical Affairs Strategy

Tanja Obradovic, Vice President of Oncology Scientific Affairs at ICON PLCh, shared a post by…

Nov 2, 2024, 09:27 | Blog

FDA Grants Fast Track Designation to Cothera Bioscience's PC-002

On October 23th the U.S. Food and Drug Administration (FDA) has granted Fast Track designation…

Oct 31, 2024, 08:27 | Drugs

FDA grants accelerated approval to asciminib for newly diagnosed CML

On October 29, 2024, the FDA granted accelerated approval for asciminib (Scemblix, Novartis AG) to…

Oct 29, 2024, 21:00 | Positive

Steven O'Day: At the Forefront of Immunotherapy

Dr. Steven O'Day, an immunotherapy pioneer and medical oncologist, is the Chief Medical Officer at…

Oct 28, 2024, 14:26 | Insight

Faran Polani: Inspiring day at the FDA White Oak campus

Faran Polani, Hematology and Oncology Fellow at Inova Schar Cancer Institute, shared on X: “Incredibly…

Oct 28, 2024, 08:58 | Insight

Five articles suggested by Yüksel Ürün

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey.…

Oct 26, 2024, 15:59 | Insight

Jean-Charles Soria: Key insights into the toxicity, efficacy, stability, distribution, and fate of ADCs

Jean-Charles Soria, Senior Vice President and Oncology Therapeutic Area Head at Amgen, shared a post…

Oct 26, 2024, 10:04 | Blog

Celebrating Penny’s inspiring journey and dedication to research excellence at Sarah Cannon Research Institute

Sarah Cannon Research Institute shared a post on LinkedIn: "We are excited to share the latest…

Oct 24, 2024, 10:40 | Blog

Gevorg Tamamyan: Honored to interview the Director of the FDA's Oncology Center of Excellence, Richard Pazdur

Gevorg Tamamyan shared on LinkedIn: "This year, Dr. Pazdur celebrates his 25th anniversary at the…

Oct 23, 2024, 15:44 | Drugs

FDA approves Novocure’s treatment for mNSCLC

The FDA has granted approval for Novocure's Optune Lua as a treatment option for metastatic…

Oct 23, 2024, 14:12 | Insight

Rahul Gosain: The FDA approval of Tarlatama for SCLC with Misty Shields

Rahul Gosain, Con- Host of the Oncology Brothers podcast, shared on LinkedIn: “LungCancer: Here we…

Oct 22, 2024, 16:31 | Blog

The biology and the role of biomarkers in SCLC - LUNGevity Foundation

LUNGevity Foundation shared a post on X: ''Join us for a Facebook Live on 11/1…

Oct 19, 2024, 15:57 | Insight

FDA Approves Tumor Treating Fields for Advanced NSCLC: Insights from the LUNAR Trial

The FDA has approved tumor treating fields (TTFields; Optune Lua) in combination with docetaxel or…

Oct 19, 2024, 02:16 | Blog

Real honor to meet Dr. Pazdur at AACR Annual Meeting

Wafik S. El-Deiry shared a post on X: "Real honor to meet Dr. Pazdur after…

Oct 18, 2024, 14:02 | Drugs

The CityU iGEM Team is Back in 2024 - The Babak Lab

The Babak Lab shared a post on LinkedIn: "The CityU iGEM Team is Back in 2024!…

Oct 17, 2024, 14:28 | Blog

Rahul Gosain: The FDA approval of Axatilimab and latest advancements in GVHD with Shernan Holtan

Rahul Gosain posted on LinkedIn: "Hematology: Here Rohit Gosain and I the FDA approval of Axatilimab…

Oct 16, 2024, 14:49 | Blog

Oncology Accelerated Approval Confirmatory Trials - FDA

FDA posted on LinkedIn about recent paper by Gautam Mehta and Richard Pazdur, titled "Oncology Accelerated Approval…

Oct 15, 2024, 21:29 | Insight

The 13th Annual Winship Gastrointestinal Cancer Symposium

The 13th Annual Winship Gastrointestinal Cancer Symposium took place on October 12, 2024, at the…

Oct 15, 2024, 18:54 | Blog

Shahrin Ahmed on combination therapy for Triple Negative Breast Cancer treatment

Shahrin Ahmed, Medical Specialist Oncology, Canadian Cancer Society, shared a post on X: "Triple-negative breast…

Oct 13, 2024, 05:49 | Blog

Inavolisib now FDA approved based off INAVO120 - Oncology Brothers

Oncology Brothers shared on X: "Inavolisib now FDA approved based off INAVO120: Ph III, Inavolisib…

Oct 12, 2024, 10:30 | Insight

FDA Approves Inavolisib with Palbociclib and Fulvestrant for Advanced Breast Cancer

On October 10, 2024, the FDA approved inavolisib (Itovebi, Genentech, Inc.) in combination with palbociclib…

Oct 9, 2024, 12:05 | Blog

Janet Woodcock has joined the Board of Directors of Every Cure

Janet Woodcock recently joined the Every Cure Board of Directors, focused on "rediscovering" old drugs.…

Oct 8, 2024, 11:35 | Insight

Pathways of drug development in Oncology specifically looking into time and nature of initial FDA approval, summarised by Tanja Obradovic

Tanja Obradovic shared a post on LinkedIn: "Insightful article just published by authors from National Pharmaceutical…

Oct 5, 2024, 08:59 | Insight

Palvella is the recipient of an FDA Orphan Product Grant up to $2.6 million

Palvella Therapeutics shared on LinkedIn: “Today, we announced Palvella is the recipient of an FDA…

Oct 5, 2024, 08:24 | Insight

Tanja Obradovic: New Treatment for NSCLC Patients Targeting cMet Over-Expression

Tanja Obradovic shared a post on LinkedIn: "Novel antibody-drug conjugate (ADC) may be coming for…

Oct 4, 2024, 17:28 | Blog

Raffaele Colombo: sBLA for T-DXd has been accepted by FDA HER2-low or HER2-ultralow breast cancer

Raffaele Colombo shared a post on X: "sBLA for trastuzumab deruxtecan (T-DXd) has been accepted…

Oct 4, 2024, 15:19 | Blog

Tanja Obradovic: FDA granted approval to selpercatinib for advanced or metastatic medullary thyroid cancer with a RET mutation

Tanja Obradovic shared a post on LinkedIn: "Outstanding news for patients with metastatic medulary thyroid…

Oct 3, 2024, 13:59 | Dialogues

Advancing Oncology Trials: Innovative Designs and Breakthroughs in Cancer Research

In this engaging talk, the speaker Prof. Richard Sullivan from King's College London shares insights…

Oct 3, 2024, 07:22 | Blog

Tanja Obradovic: AbbVie submitted telisotuzumab vedotin in adult NSCLC patients with tumors with EGFR non squamous histology

Tanja Obradovic shared a post on LinkedIn: "Completely new treatment option by novel antibody-drug conjugate (ADC)…

Oct 2, 2024, 15:39 | Blog

Tanja Obradovic: FDA ODAC's decision on PD-1 Inhibitors in HER2- Negative Gastric Cancer

Tanja Obradovic shared a post on LinkedIn: "In highly anticipated discussion on September 26th FDA Oncologic Drugs…

Oct 2, 2024, 08:24 | Blog

Tanja Obradovic: FDA just approved Osimertinib for adult patients with locally advanced, unresectable non-small cell lung cancer

Tanja Obradovic shared a post on LinkedIn: ''FDA just approved Osimertinib (Tagrisso), a third-generation EGFR-directed…

Oct 1, 2024, 10:44 | Blog

The FDA-ASCO virtual workshop starts today!

ASCO posted on LinkedIn: "The FDA-ASCO virtual workshop starts tomorrow! Explore the impact of cancer…

Oct 1, 2024, 08:28 | Blog

Daniel Michaeli: Key takeaways from our new article on breast cancer drugs

Daniel Michaeli shared a post on LinkedIn, about a recently published paper: Breast cancer drugs:…

Sep 30, 2024, 08:39 | Opinion

Tanja Obradovic: Strategy of clinical development in oncology requires global considerations

Tanja Obradovic shared the following on LinkedIn: “Strategy of clinical development in oncology always encompasses…

Sep 29, 2024, 16:20 | Insight

Elvina Almuradova: Using ICis as a first-line treatment may pose a risk of toxicity in unresectable ESCC

Elvina Almuradova, Associate Professor of Oncology at Medicana Sağlık Grubu, shared a post on LinkedIn:…

Sep 29, 2024, 15:24 | Blog

Vivek Subbiah: "Bringing the Best Minds Together to Tackle Cancer" at the United Nations General Assembly

Vivek Subbiah shared a post on LinkedIn: "I was deeply honored and excited to have…

Sep 29, 2024, 11:16 | Blog

OncoInfluencers to Follow on Social Media: Dr. Tatiana M. Prowell

We are excited to feature Dr. Tatiana M. Prowell as a distinguished voice in the…

Sep 27, 2024, 15:04 | Blog

Joshua Bauml: The U.S. FDA approved our targeted therapy in combination with for NSCLC with specific EGFR mutations

Joshua Bauml, Vice President, Lung Cancer Disease Area Stronghold (DAS) Leader, shared a post on…

Sep 26, 2024, 11:19 | Blog

Immunotoxin moxe for patients with relapsed or refractory hairy cell leukemia is now FDA approved - NCI Center for Cancer Research

NCI Center for Cancer Research shared a post on LinkedIn: "BREAKTHROUGH IN TREATMENT: In 2012, Senior…

Sep 25, 2024, 02:31 | Insight

Jennifer Doudna on Advancing CRISPR at Fred Hutchinson Cancer Centre

Fred Hutchinson Cancer Center shared a post on X: “Nobel Laureate Jennifer A. Doudna kicked…

Sep 24, 2024, 11:04 | Blog

Stephen V Liu: The recent FDA approval of the MARIPOSA-2 regimen for EGFR NSCLC

Stephen V Liu shared a post on X: ''In this episode of the IASLC podcast…

Sep 24, 2024, 09:03 | Blog

Vas Narasimhan: US FDA has approved our CDK4/6 inhibitor to reduce risk of recurrence in people with HR+/HER2 early breast cancer

Vas Narasimhan posted on LinkedIn: "I’m proud to share the news that the US FDA…

Sep 24, 2024, 00:05 | Blog

Rahul Gosain: Amivantamab and Chemo now FDA approved in 2L mEGFR NSCLC after Osimertinib

Rahul Gosain posted on LinkedIn: "Amivantamab and Chemo now FDA approved in 2L mEGFR NSCLC…

Sep 19, 2024, 11:55 | Insight

Aakash Desai: Efficacy, Innovation and Cost of FDA-Approved NSCLC Drugs

Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn: “We're excited to…

Sep 17, 2024, 16:06 | Blog

Xiuning Le: BAY88 has received USA FDA and Chinese NMPA BTD status for pre-treated HER2-mutant NSCLC

Xiuning Le shared a post by Bayer Oncology on LinkedIn, adding: "BAY88 has received USA FDA and…

Sep 16, 2024, 14:19 | Blog

Mamtha Balla: Invasive Fusarium in immuno-compromised patients

Mamtha Balla, Transplant Oncology-ID fellow at MD Anderson Cancer Center, shared a post on X:…

Sep 16, 2024, 13:24 | Dialogues

OncoDaily: France Bureau // vol.1

Tatev-Sargsyan Lefort presents the latest oncology news roundup from the past week, with a focus…

Sep 15, 2024, 15:58 | Blog

OncoInfluencers to Follow on Social Media: Dr. Neeraj Agarwal

We are delighted to feature Dr. Neeraj Agarwal as a key figure in the oncology…

Sep 13, 2024, 19:19 | Blog

Advances in cancer care must consider the impact on patients’ reproductive health - ASCO

ASCO - American Society of Clinical Oncology made the following post on LinkedIn: “Advances in cancer care…

Sep 10, 2024, 10:28 | Blog

Matthew Herper: Facing cancer is hard -- even if you're someone who would change the way we treat cancer

Matthew Herper, Senior Writer, Medicine, and Editorial Director, Events at STAT, made the following post…

Sep 9, 2024, 13:41 | Dialogues

Dr. Vivek Subbiah on Pioneering Precision Oncology and Global Clinical Trials | OncoInfluencers #13

Dr. Vivek Subbiah, Chief of Early Phase Drug Development at Sarah Cannon Research Institute, joins…

Sep 4, 2024, 11:43 | Blog

Rochelle G Prosser: I am excited to speak about Precision Oncology at the FNIH's Team Science Day

Orchid Healthcare Solutions shared a post by Rochelle G Prosser, Founder, CEO at Orchid Healthcare…

Sep 3, 2024, 13:39 | Blog

Herbert Loong: A very important resource for oncology drug developers globally

Herbert Loong shared a post on X: "A very important resource for oncology drug developers globally.…

Sep 2, 2024, 19:15 | Insight

Patrick Hwu: How does anti-CTLA-4 and anti-PD-1 combination work mechanistically?

Patrick Hwu shared a post on LinkedIn: “The combination of anti-CTLA-4 and anti-PD-1 antibodies is…

Sep 2, 2024, 07:22 | Blog

Chris Hourigan: Build your cancer research program at the new Virginia Tech Fralin Biomedical Research Institute Cancer Research Center

Chris Hourigan, Director, Virginia Tech FBRI Cancer Research Center (DC), Virginia Tech shared a post…

Sep 1, 2024, 16:37 | Blog

Advancements in Medical Treatments, Neuroscience, and the Power of Metals - The Babak Lab

The Babak Lab shared a post on LinkedIn: ''Weekly Digest: Advancements in Medical Treatments, Neuroscience,…

Sep 1, 2024, 16:26 | Blog

Vivek Subbiah: Clinical trial vs fiction

Vivek Subbiah shared an article on LinkedIn: ''Every single drug, medicine, and treatment you’ve ever…

Aug 31, 2024, 14:15 | Insight

Tumour-agnostic authorised indications by FDA and EMA

Elisa Agostinetto shared a post on X about a recent paper by Benedikt Westphalen et…

Aug 29, 2024, 17:43 | Insight

FDA’s latest approvals summarized by Samuel Hume

Samuel Hume, Researcher at the University of Oxford, recently shared on X: “The FDA approved 4…

Aug 28, 2024, 17:09 | Blog

Tanja Obradovic: Importance of vigilant toxicity monitoring

Tanja Obradovic shared a post on LinkedIn: "Importance of vigilant toxicity monitoring as well as early…

Aug 27, 2024, 22:42 | Drugs

Maria Babak: Approval of axatilimab-csfr is a significant development in the treatment of cGVHD

Maria Babak shared a post by The Babak Lab on LinkedIn: "This is a significant…

Aug 26, 2024, 19:50 | Blog

Tanja Obradovic reflects on first KRAS G12C mutation inhibitor approval

Tanja Obradovic posted on LinkedIn: "First KRAS G12C mutation inhibitor just got approval in China.…

Aug 25, 2024, 16:32 | Blog

Francisco J. Esteva: Capivasertib combined with fulvestrant offers new hope in breast cancer

Francisco J. Esteva, Chief, Division of Hematology and Medical Oncology at Lenox Hill Hospital shared a…

Aug 24, 2024, 11:47 | Insight

Narjust Florez: Discussion with Julia Rotow about the MARIPOSA trial

Narjust Florez shared a post by IASLC on X, adding: “At The International Association for…

Aug 24, 2024, 11:15 | Insight

Jill Feldman: Exciting news for the EGFR lung cancer community

Luis E. Raez, Medical Director at Memorial Cancer Institute, shared a post by Jill Feldman on…

Aug 24, 2024, 10:51 | Insight

Shahrin Ahmed: High health care utilization and poor survival rate in older adults with AML

Shahrin Ahmed, Medical Specialist at the Canadian Cancer Society, shared a post on X: “Older…

Aug 23, 2024, 17:15 | Blog

Brian Shields: AI evaluates recent FDA decision

Brian Shields, Creator of KOL Pulse AI, shared on LinkedIn: "AI evaluates recent FDA decision:…

Aug 23, 2024, 14:21 | Drugs

Stephen V Liu: How do we select the optimal regimen for EGFR NSCLC?

Stephen V Liu shared on X: "With FLAURA (osimertinib alone), FLAURA2 (osimertinib with chemotherapy), and…

Aug 23, 2024, 14:20 | Blog

FDA Approves Johnson & Johnson's Chemotherapy-Free Regimen for EGFR-Mutated Lung Cancer

Kiran Patel, Vice President of Clinical Development in Solid Tumor Franchise at The Janssen Pharmaceutical…

Aug 21, 2024, 14:03 | Blog

$3 million research grant to Dana-Farber Cancer Institute and UT Health San Antonio to study BRCA therapy

Dana-Farber Cancer Institute shared on LinkedIn: "Scientists at Dana-Farber's Center for BRCA and Related Genes in…

Aug 21, 2024, 13:57 | Blog

AACR - Broadening eligibility criteria for cancer clinical trials may better demonstrate how a drug will affect a real-world population

American Association for Cancer Research shared on LinkedIn: "Broadening eligibility criteria for cancer clinical trials allows…

Aug 20, 2024, 14:50 | Drugs

Key takeaways from the FDA approval of dostarlimab-gxly in endometrial cancer - The Babak Lab

The Babak Lab shared on LinkedIn: "FDA Expands Endometrial Cancer Treatment: The FDA has approved…

Aug 20, 2024, 10:46 | Insight

Houman Sotoudeh: MRI Math, AI Platform-Cyber Device for GBM is now FDA-approved

Houman Sotoudeh, Associate Professor of Neuroradiology and Neurology at University of Alabama at Birmingham, shared…

Aug 17, 2024, 09:13 | Positive

Harpreet Singh: Exciting news in colorectal cancer treatment

Harpreet Singh, Chief Medical Officer at Precision For Medicine, shared a post on LinkedIn: "Exciting…

Aug 16, 2024, 18:50 | Blog

Kai Chen received the 1st place student paper award from the ASA Biopharmaceutical Section

Kai Chen shared a post on LinkedIn: "It is a great honor to receive the…

Aug 14, 2024, 18:31 | Blog

Jennifer Bires about FDA’s recent decision on MDMA

Jennifer Bires, Executive Director of Life with Cancer and Patient Experience at Inova Schar Cancer…

Aug 14, 2024, 15:35 | Blog

Vincent Rajkumar: Updated Active Drugs in myeloma with mechanism of action

Vincent Rajkumar shared a post on X: "Updated Active Drugs in myeloma with mechanism of…

Aug 12, 2024, 07:28 | Dialogues

Immunotherapy in Soft Tissue - 5 min Sarcoma Talk #6 with Sandra D'Angelo

In the new episode of "5 Minute Sarcoma Talk", Dr. Shushan Hovsepyan, the Editor-in-Chief of…

Aug 12, 2024, 01:35 | Blog

Joshua Zeidner: Highly impactful data for R/R AML and menin inhibitors

Joshua Zeidner, Associate Professor at UNC Lineberger, shared a post by Ghayas Issa, Leukemia Physician at MD…

Aug 11, 2024, 12:39 | Blog

Ryan Locke: New ARPA-H funding opportunity in cancer screening

Ryan Locke, Associate at Booz Allen Hamilton, posted on LinkedIn: "New ARPA-H funding opportunity in…

Aug 11, 2024, 12:09 | Insight

Weekly digest breakthroughs in cancer treatment, chemistry, and more by The Babak Lab

Maria Babak shared a post by The Babak Lab, on LinkedIn adding: “Let's recap on…

Aug 10, 2024, 11:58 | Insight

Botensilimab: A Revolutionary Fc-Enhanced CTLA-4 Inhibitor Transforming Cancer Immunotherapy

In the rapidly evolving landscape of oncology, we are witnessing remarkable advancements in various treatment…

Aug 10, 2024, 11:10 | Insight

Shahrin Ahmed: Multiple myeloma treatment with Darzalex Faspro has been approved by the FDA

Shahrin Ahmed, Medical Specialist at the Canadian Cancer Society, shared a post on X: "Multiple…

Aug 10, 2024, 08:21 | Blog

Susan Pandya: The beginning of a new era for patients living with grade 2 IDH-mutant glioma

Susan Pandya, Vice President of Clinical Development and Global Head of Cancer Metabolism at Servier,…

Aug 8, 2024, 12:35 | Blog

Miguel Bronchud: Liquid biopsy to detect early breast cancers

Miguel Bronchud, Co-Founder and Advisory Board at Regenerative Medicine Solutions, shared a post on LinkedIn,…

Aug 6, 2024, 16:11 | Insight

Daniel Peeper: Therapeutic approaches combined with PD1 axis blockade to provide synergistic clinical benefit

Daniel Peeper, Head of the Division of Molecular Oncology and Immunology at the Netherlands Cancer…

Aug 6, 2024, 11:47 | Drugs

FDA Grants Accelerated Approval to Afamitresgene Autoleucel (TECELRA) for Treating Advanced Synovial Sarcoma

On August 2, 2024, the FDA made history by granting accelerated approval to afamitresgene autoleucel…